Recently, the French national network for oculo-cerebral lymphomas (LOC) reported the first and largest cohort of nine immunocompetent patients with relapsed/refractory PCNSL treated with CD19 CAR-T cells (tisa-cel and axi-cel), after at least two previous lines of therapy [68] (Table 1). The gene discussed is CD19; the disease is primary central nervous system lymphoma.